San Francisco, California, USA, October 30, 2026 / PRNewswire / -- IDEAYA Biosciences, Inc. (Nasdaq ticker: IDYA) is a company focused on precision medical oncology, dedicated to the discovery, development, and commercialization of targeted therapies. The company announced today that on October 29, 2026, the IDEAYA Board of Directors Compensation Committee granted a total of 99,600 non-qualified stock options in common company stock to 4 newly hired employees.
These stock options are granted in accordance with IDEAYA Biosciences and Inc. The 2023 Employment Incentive Award Plan (2023 Inducement Plan) serves as an incentive for these individuals to join IDEAYA, and comply with NASDAQ listing rule 5635(c)(4).
The 2023 Incentive Plan is solely intended to grant equity rewards to individuals who were not previously IDEAYA employees, or those who rejoined the company after their official resignation period, as an incentive for them to join IDEAYA. This is in accordance with NASDAQ Listing Rule 5635(c)(4).
The exercise price of these stock options is $32.89 per share, which is consistent with the closing price of the IDEAYA common shares on NASDAQ Global Select Market on the grant date. The option period is 10 years, and the options will vest over 4 years. Of this, 25% of the options will vest on the first anniversary of the vesting start date, while the remaining 75% will vest equally over the following 3 years. The vesting of the options is conditional upon the relevant employees continuing to serve for IDEAYA on each vesting date.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company dedicated to discovering, developing, and commercializing transformative cancer treatment solutions. The company's approach combines expertise in small molecule drug discovery, structural biology, and bioinformatics, and is equipped with strong internal capabilities for identifying and validating translational biomarkers, in order to develop customized, potentially first-in-class targeted therapies that match the genetic drivers of the disease. The company has established a robust product pipeline, with a focus on synthetic lethality and antibody-drug conjugates (ADC), for molecularly defined solid tumor indications. The company's mission is to bring forth the next generation of more selective, more effective, and highly personalized precision oncology therapies, with the goal of altering the course of the disease and improving the clinical outcomes for cancer patients.
Investors contact the media
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[ email protected ]
